eligibility_summary
Eligible: <=21 yrs with relapsed/refractory CD70+ hematologic malignancy (AML/MDS, B-ALL or lymphoma if CD19-/dim or CD19-therapy-ineligible, T-ALL, MPAL), incl >=2nd relapse or post-allo-HSCT. Life expectancy >12 wks, Karnofsky/Lansky >=50, recovered from allo-HCT, no active GVHD, no DLI <28d, HCT donor identified, negative pregnancy test, not lactating. Exclude: primary immunodeficiency, HIV, severe infection, cornstarch/HES allergy, APL, contraindication to Flu/Cy.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Interventions: autologous CD70-targeted CAR T-cell therapy following lymphodepleting chemotherapy (fludarabine + cyclophosphamide) with mesna uroprotection. Mechanisms: CD70-CAR T cells are gene-modified T lymphocytes that recognize CD70 on tumor cells and, upon binding, activate T-cell effector functions (cytotoxic killing and proliferation) to eradicate CD70+ disease. Fludarabine (purine analog antimetabolite) and cyclophosphamide (alkylating agent) provide lymphodepletion via DNA damage-induced cytotoxicity that reduces host lymphocytes/regulatory cells and supports CAR T expansion, mesna scavenges acrolein to prevent cyclophosphamide-induced cystitis. Targets/pathways: CD70 (TNFSF7) on malignant hematologic cells (AML/MDS, B-ALL, T-ALL, MPAL, lymphoma), engaging the CD27-CD70 axis, includes marrow and extramedullary disease, with relevance for CD19-negative/dim B-lineage cases.